Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹301.80
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹12.97B
Enterprise Value₹12.92B
Total Cash (Recent Filing)₹1.59B
Total Debt (Recent Filing)₹88.36M
Price to Earnings (P/E)28.8
Beta1.05
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)1.64
Shares Outstanding66,962,250
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)6.09
Price to Sales (P/S)5.44
P/FCF Ratio26.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & ProfitabilityConsistent revenue growth and healthy gross and net margins indicate durable demand for the company’s branded formulations and disciplined cost control. Over a multi-quarter horizon this supports reinvestment in sales, stable operating leverage, and persistent earnings power.
Strong Balance SheetLow leverage and a high equity ratio provide financial flexibility and reduce refinancing risk. This capital structure enables the company to fund capex or acquisitions, withstand cyclical downturns, and support consistent operations without material interest-coverage pressure.
Cash GenerationEffective conversion of earnings into operating and free cash flow enhances internal funding for growth, dividends, and working capital. Reliable cash generation underpins sustainable capital allocation and reduces dependence on external financing over the medium term.
Bears Say
Declining Cash ReservesEroding cash buffers undermine short-term liquidity and limit the firm’s ability to absorb shocks or seize opportunistic investments. Over several quarters this may force reliance on working-capital lines or constrain discretionary spending, raising financing risk.
Negative EPS GrowthA substantial decline in EPS signals earnings volatility or earnings compression that can persist absent structural fixes. Over months this can limit retained earnings, weaken per-share returns, and pressure management to restore profitability or adjust capital allocation.
Variable Free Cash FlowInconsistent free cash flow complicates planning for reinvestment, dividends, and debt reduction. Structural variability in FCF increases the chance the company will need intermittent external funding or curtail investments, which can impede sustained growth execution.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹301.80 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹12.97B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is May 26, 2026 which is in 45 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Jan 21, 2026. The company reported ₹1.64 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.64.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 1.24%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 66,962,250 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹1.64 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.029%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.
Technical Analysis
Bajaj Healthcare Ltd
―
Bliss Gvs Pharma Limited
―
Hester Biosciences Limited
―
Lincoln Pharmaceuticals Ltd
―
Themis Medicare Limited
―